MARKET WIRECNBC • 2h ago
Here are 3 big things we're watching in the stock market in the week aheadThe market could use a few victories in the days ahead, which will be filled with more earnings, an election, and jobs data.
Why CNSP Stock surged +5.77% Today — RQD Quant Desk Flash
$4.77 +5.77% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $4.81
CNS Pharmaceuticals Inc. (CNSP) carries a Roarable Rating of D (Sell) with 48/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
ROARABLE D • SELL / AVOID
Cap $7.0M
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $4.81 (+0.85%)🧬 Disciplined Float (+0.72% YoY Shares)⚙️ Cash Engine: 6/20 (E) • 0% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record Warning: Scores below 50 (48/100 · D) historically underperformed SPY in 71% of rolling 90-day windows (-5.6% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →RQD QUANT TACHOMETERSELL / AVOID • D
2-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw D- · Rk C
Each axis scored 0–20
12M PRICE TARGET CONE-4.4% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for CNSP)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (48/100 Composite)
🔍 WHY CNSP SCORES 48/100 (D) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Macro Regime Fit+15/20 pts (31% of score)
FRED Regime × Technicals: 33% of 52W Range • RSI-14 at 48.9 (NEUTRAL RANGE)
▲ #2 Bullish Driver: Whale & Options Positioning+12/20 pts (25% of score)
20D Institutional Volume Accumulation (±12.5% realized swing band)
▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution5/20 pts (-15 pt drag)
Disciplined Float (+0.72% YoY Shares) & executive Form 4 sales trim 15 pts from alignment
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade C$5.35-9.3% Next Q
56
Q2 (-2Q)Grade C-$4.85+2.5% Next Q
53
Q3 (-1Q)Grade C-$4.97-4% Next Q
51
CurrentGrade D$4.77-5.6% Hist 90D α
48
Trajectory: C (56) → D (48)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER
⚔️ Adversarial Opposing Case: What Could Spark a CNSP Turnaround Squeeze
While CNSP currently carries a cautious 48/100 (D) rating due to Insider Conviction & Share Dilution (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
🚀 Contrarian Squeeze Trigger #1
Established market leader in Health Care with deep daily trading liquidity.
🚀 Contrarian Squeeze Trigger #2
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($5.33) and Max Pain ($5.01) forces dealer call-delta covering toward $11.07.
🚀 Contrarian Squeeze Trigger #3
Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
🎲 LIVE PREDICTION MARKET ODDS TIED TO $CNSP• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “CNSP Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why CNSP Stock surged +5.77% Today — RQD Quant Desk Flash
CNS Pharmaceuticals Inc. (CNSP) surged +5.77% to $4.77, trading at 33% of its 52-week range ($1.9 – $10.54). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 33% of its 52-week range ($1.9 – $10.54) with RSI-14 at 48.9 (NEUTRAL RANGE).
- ▸Volatility Profile: Historical 20-day realized swing band of ±12.5% around $4.77 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable D (Sell) backed by 52% gross margin and $0 annual free cash flow.
Live CNSP Headlines & Catalysts
MARKET WIRECNBC • 3h ago
Democratic Rep. Stevens endorses Rogers over El-Sayed in Michigan Senate electionHaley Stevens had lost the Democratic nomination for Senate in Michigan to Abdul El-Sayed earlier this year.
RISK WATCHReuters • 4h ago
Israeli strikes kill eight people in Gaza - medics say - ReutersIsraeli strikes kill eight people in Gaza - medics say Reuters
MARKET WIREReuters • 5h ago
Russia's FSB says minor detained over park attack threat after US tip-off - ReutersRussia's FSB says minor detained over park attack threat after US tip-off Reuters
MARKET WIREReuters • 6h ago
Iran, Qatari mediators hold third day of talks to end US-Iran war - ReutersIran, Qatari mediators hold third day of talks to end US-Iran war Reuters
CATALYSTReuters • 7h ago
Qatar surges, bucking Gulf market slide on Iran war concerns - ReutersQatar surges, bucking Gulf market slide on Iran war concerns Reuters
MARKET WIREReuters • 7h ago
OPEC+ keeps December oil output targets steady ahead of tougher call for 2027 - ReutersOPEC+ keeps December oil output targets steady ahead of tougher call for 2027 Reuters
MARKET WIREReuters • 7h ago
German ministers pledge tough action after rioters damage stores in Frankfurt - ReutersGerman ministers pledge tough action after rioters damage stores in Frankfurt Reuters
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring CNSP)
- ✓Walkthrough of CNSP's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
CNSP // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +110.13%⚡ TESTING RESISTANCE
2026-10-30O $4.60H $5.01L $4.25C $4.77VOL 52.9K
RES: $5.40SUP: $3.58SMA50: $5.33SMA200: $4.59
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
CNSP Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor (#25)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle (#30)
8.0%/yr Implied 5Y Growth
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger (#33)
No active Ellis Vennor swing setup published on CNSP today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for CNSP. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for CNSP today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (CNSP)
Health Care Rank #397 of 1016
⚔️ ENVB vs CNSP Full Matrix →
1. Head-to-Head Health Care Peer Comparison (CNSP vs. ENVB, IMRN, FBLG, UPC)
Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)Across 1016 tracked Health Care securities in the Roarable RQD universe, CNS Pharmaceuticals Inc. (CNSP) ranks #397 by composite RQD confidence (48/100, grade D) and #921 by equity capitalization ($7.0M). Within this direct 5-issuer industry benchmark cohort, CNSP leads on earnings valuation at N/A trailing P/E, while CNSP leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. IMRN currently holds the highest overall quantitative score in the immediate peer group at 58/100 (D+) compared with CNSP at 48/100 (D).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| CNSP
ACTIVE
CNS Pharmaceuticals Inc. | D | 48/100 | — | — | -35.0% | +5.77% | $7.0M | Benchmark Subject |
| ENVB Enveric Biosciences Inc. | D- | 37/100 | — | — | -35.0% | -0.68% | $6.5M | /envb-vs-cnsp → |
| IMRN Immuron Limited | D+ | 58/100 | — | — | — | +2.48% | $7.4M | /imrn-vs-cnsp → |
| FBLG FibroBiologics Inc. | D- | 40/100 | — | — | -35.0% | -3.99% | $6.3M | /fblg-vs-cnsp → |
| UPC Universe Pharmaceuticals Inc. (Class A) | E | 33/100 | — | 35.3% | — | -20.21% | $7.7M | /upc-vs-cnsp → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001729427In its most recent audited fiscal period (FY2025, filed 2025-12-31), CNS Pharmaceuticals Inc. (CNSP) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$16.0K, operating cash flow of -$13.8M, and free cash flow of -$13.8M (+19.2% YoY). On the balance sheet, CNSP closed FY2025 with $8.6M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 1/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $0 | -$16.0K | -$13.8M | -$13.8M | $8.6M | — |
| FY2024 (FY) | 2024-12-31 | $0 | -$14.9K | -$17.1M | -$17.1M | $8.7M | — |
| FY2023 (FY) | 2023-12-31 | $0 | -$18.9K | -$14.1M | -$14.1M | — | — |
3. CNSP Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs CNSP stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-01, CNS Pharmaceuticals Inc. (NASDAQ: CNSP) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 48/100 at a spot price of $4.77 (+5.77% 1D, market cap $7.0M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 12/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 15/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, CNSP ranks #397 in composite RQD confidence.
How does CNSP compare to ENVB and IMRN in the Health Care sector?
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), CNSP carries a Roarable D (48/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, ENVB (Enveric Biosciences Inc.) holds a D- grade (37/100 RQD, P/E N/A, ROIC -35.0%, cap $6.5M) and IMRN (Immuron Limited) posts a D+ grade (58/100 RQD, P/E N/A, ROIC —, cap $7.4M). Among the 5-stock peer group, CNSP leads on earnings multiple (N/A) while CNSP leads on capital efficiency (-35.0% ROIC).
What are the biggest fundamental strengths and SEC risk factors for CNSP?
Per CNSP's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001729427), CNS Pharmaceuticals Inc. generated $0 in revenue, -$16.0K in net income, and -$13.8M in free cash flow against $8.6M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Where is CNSP trading relative to its 50-day, 200-day, and 52-week technical levels?
CNSP last traded at $4.77 (+5.77% on volume of 46,398 shares), positioning the stock -10.51% below its 50-day simple moving average ($5.33) and +3.92% above its 200-day simple moving average ($4.59). Across its 52-week range of $1.90 to $10.54, CNSP sits at the 33.2% percentile with a 14-day RSI of 48.9 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($4.17 to $5.37).
CNSP Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is CNSP stock moving today?
Why CNSP Stock surged +5.77% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.